Literature DB >> 12408422

What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder.

Mark A Zamorski1, Ronald C Albucher.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are the drug of choice for treatment of patients with panic disorder. Most patients have a favorable response to SSRI therapy; however, 30 percent will not be able to tolerate these drugs or will have an unfavorable or incomplete response. Strategies to improve management of such patients include optimizing SSRI dosing (starting at a low dose and slowly increasing the dose to reach the target dose) and ensuring an adequate trial before switching to a different drug. Benzodiazepines should be avoided but, when necessary, may be used for a short duration or may be used long-term in patients for whom other treatments have failed. Slower-onset, longer-acting benzodiazepines are preferred. All patients should be encouraged to try cognitive behavior therapy. Augmentation therapy should be considered in patients who do not have a complete response. Drugs to consider for use in augmentation therapy include benzodiazepines, buspirone, beta blockers, tricyclic antidepressants, and valproate sodium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408422

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  7 in total

1.  Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. the HUNT study, Norway.

Authors:  Aslak Johansen; Jostein Holmen; Robert Stewart; Ottar Bjerkeset
Journal:  Eur J Epidemiol       Date:  2011-12-20       Impact factor: 8.082

2.  Knowledge About Recommended Treatment and Management of Major Depressive Disorder, Panic Disorder, and Generalized Anxiety Disorder Among Family Physicians.

Authors:  David Katerndahl; Robert L. Ferrer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

3.  Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment.

Authors:  S B Sartori; N Whittle; A Hetzenauer; N Singewald
Journal:  Neuropharmacology       Date:  2011-08-04       Impact factor: 5.250

Review 4.  Neuropsychiatric consequences of cardiovascular medications.

Authors:  Jeff C Huffman; Theodore A Stern
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

5.  Single-step extraction for simultaneous quantification of desvenlafaxine and alprazolam in human spiked plasma by RP-HPLC.

Authors:  Huma Rao; Saeed Ahmad; Asadullah Madni; Imtiaz Ahmad; Muhammad Nadeem Shahzad
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

6.  Pharmacological management of panic disorder.

Authors:  Carlo Marchesi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

7.  Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report.

Authors:  Dushad Ram; Shwetha Patil; Basavana Gowdappa; Iyshwarya Rajalakshmi
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-12-31       Impact factor: 2.582

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.